Algorithm for diagnostics and systemic therapy of metastatic hormone-sensitive HER2-negative breast cancer

G.A. Dashyan, A.A. Olchonova, E.S. Dzhelyalov, R.M. Akhmedov, O.A. Sereda, A.B. Vats, A.S. Zhurov, L.F. Shaikhelislamova, G.A. Pushkaruk, A.M. Belousov

N.I. Pirogov Clinic of High Medical Technologies, St. Petersburg State University, St. Petersburg, Russia

Modern methods of systemic therapy of metastatic breast cancer (mBC) include the use of various combinations of chemotherapy, hormonal therapy, targeted and immunotherapy. The development and introduction of new therapeutic agents continue to change the standards of treatment and open new horizons for an individualized approach to therapy. This article considers the features of diagnostics, available treatment options for hormone-sensitive HER2-negative mBC and promising new treatment methods.

Keywords

About the Authors

Corresponding author: Garik A. Dashyan, Dr. Sci. (Med.), Oncologist, Head of the oncology department No. 1, N.I. Pirogov Clinic of High Medical Technologies, St. Petersburg State University, St. Petersburg, Russia; dgarik@mail.ru

Similar Articles